EU approves Danish plan to put EUR 108m behind Bavarian Nordic's Covid-19 vaccine

The Danish state's plan to award EUR 108m to support phase III studies of Bavarian Nordic's covid-19 vaccine has been approved by the EU Commission.

Photo: Philip Davali/Ekstra Bladet

The EU Commission, which works alongside competition authorities from member states, announced on Monday that it will allow the Danish state to offer Bavarian Nordic EUR 108m to support the development of its Covid-19 vaccine.

"This EUR 108m Danish aid measure will contribute to much needed research and development activities to respond to the coronavirus outbreak. We continue working in close cooperation with member states to find workable solutions to mitigate the economic impact of the coronavirus outbreak, in line with EU rules," says Margrethe Vestager, who is Executive Vice-President in charge of competition policy, in a press release.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

In a world of options, Genmab's CEO chose partnerships

In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.

Further reading

Related articles

Latest news

See all jobs